Content uploaded by Vincenzo De Leo
Author content
All content in this area was uploaded by Vincenzo De Leo on Nov 15, 2017
Content may be subject to copyright.
Women’s Health Care
Leo et al., J Women’s Health Care 2014, 3:5
http://dx.doi.org/10.4172/2167-0420.1000182
Volume 3 • Issue 5 • 1000182
J Women’s Health Care
ISSN: 2167-0420 JWHC, an open access journal
Open Access
Research Article
Phyto-Oestrogens and Chaste Tree Berry: A New Option in the Treatment
of Menopausal Disorders
Vincenzo De Leo*, Valentina Cappelli, Alessandra Di Sabatino and Giuseppe Morgante
Molecular Medicine and Development Department, Obstetrics and Gynecology Clinic, University of Siena, Italy
Abstract
For a woman, menopause represents a transitional phase from a fertile to a non-fertile age, in which there is a
gradual reduction in ovarian function accompanied by a gradual cessation of oestrogen production.
The clinical presentation can involve a series of disorders, including hot ushes with episodes of sweating,
particularly at night, palpitations, changes in sleep-wake rhythm, irritability, anxiety and mood changes, vaginal dryness
due to a process of progressive atrophy with thinning of the outer and inner labia, reduction of vascularisation and
elastic bres, and decreased sexual desire; subsequently, Many women use alternative therapies to treat hot ushes
and other menopausal symptoms. The purpose of this review is to summarize current information on the efcacy and
safety of phytoestrogens and the herbal medicine. Given the importance that these symptoms assume for the woman,
not only for the perceived quality of life, but also for the increased risk of developing all the diseases, all the treatments
adopted for menopausal women are directed primarily to resolving vasomotor disorder
*Corresponding author: Prof Vincenzo De Leo, Molecular Medicine and
Development Department, University of Siena, Italy, Tel: +390577233465; Fax:
+390577233454; E-mail: vincenzo.deleo@unisi.it
Received February 26, 2014; Accepted August 14, 2014; Published August 18,
2014
Citation: Leo VD, Cappelli V, Sabatino AD, Morgante G (2014) Phyto-Oestrogens
and Chaste Tree Berry: A New Option in the Treatment of Menopausal Disorders. J
Women’s Health Care 3: 182. doi:10.4172/2167-0420.1000182
Copyright: © 2014 Leo VD, et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and
source are credited.
Keywords: Menopause; Vasomotor symptoms; Hot ushes; Phyto-
oestrogens; Magnolia; Chaste tree berry
Introduction
For a woman, menopause represents a transitional phase from
a fertile to a non-fertile age, in which there is a gradual reduction in
ovarian function accompanied by a gradual cessation of oestrogen
production [1]. During this period, women are faced with irregular
ovulatory or anovulatory cycles without a systematic progression from
one to the other.
e mean age of onset of this phase is 40 to 50 years and it is certainly
the most vulnerable period in a woman’s life in that hormone deciency
causes neuroendocrine changes that constitute the pathophysiological
basis of neurovegetative disorders (Figure 1).
e clinical presentation can involve a series of disorders, including
hot ushes with episodes of sweating, particularly at night, palpitations,
changes in sleep-wake rhythm, irritability, anxiety and mood changes,
vaginal dryness due to a process of progressive atrophy with thinning
of the outer and inner labia, reduction of vascularisation and elastic
bres, and decreased sexual desire; subsequently, the process of atrophy
also aects the epidermis with thin, pale skin that is easily susceptible
to bacterial and viral infections. A similar condition is observed in the
vagina with a reduction in thickness of the mucosa, which becomes
atrophic with reduced vascularisation and results in dyspareunia (Table
1) [2].
Among the most important long-term complications, attention
should be drawn to the loss of minerals and consequent reduction in
bone mass, which is associated with osteopenia and osteoporosis of
varying degrees and dysfunction and atrophy of the genitourinary tract.
With the passage of time, oestrogen deciency in fact accelerates the
process of bone demineralisation, as oestrogens promote the absorption
of calcium in the intestine and the mineralisation process in bone [3].
e most common symptoms of menopause, even when taking
into account all the dierent populations studied, are hot ushes, which
aect between 65% and 86.8% of the menopausal female population,
whereas night sweats aect between 65% and 82.1%, insomnia between
61% and 67.8% and mood changes between 57% and 47.5% [4,5].
e symptom for which postmenopausal women most frequently
visit their doctor for relief is the occurrence of hot ushes [6]. is
symptom is present in more than 80% of women entering into
physiological menopause, while it aects more than 90% of women who
have undergone surgical removal of the ovaries. Menopausal symptoms
must not be regarded simply as disorders associated with deterioration
in the quality of the life, but also as a risk factor for the development of
osteoporosis, as well as cardiovascular diseases and brain deterioration
[7,8].
Figure 1: Main changes in the neuroendocrine axis in menopause.
Citation: Leo VD, Cappelli V, Sabatino AD, Morgante G (2014) Phyto-Oestrogens and Chaste Tree Berry: A New Option in the Treatment of Menopausal
Disorders. J Women’s Health Care 3: 182. doi:10.4172/2167-0420.1000182
Page 2 of 6
Volume 3 • Issue 5 • 1000182
J Women’s Health Care
ISSN: 2167-0420 JWHC, an open access journal
A review from 2009 on this subject shows that more severe hot
ushes can be correlated with rapid bone loss and the subsequent
development of osteoporosis within a short period of time [9]; they
are also related to a weaker verbal memory [10] and reduced levels
of plasma antioxidants, but also to an increased cardiovascular stress
response and to changes in blood pressure.
e vasomotor symptoms are also correlated with a signicant
increase in the risk of coronary heart disease, which does not appear
to be entirely explicable by other risk factors for coronary heart disease
[11].
Given the importance that these symptoms assume for the woman,
not only for the perceived quality of life, but also for the increased risk
of developing all the diseases listed above, all the treatments adopted
for menopausal women are directed primarily to resolving vasomotor
disorders.
Changes in ermoregulation During Menopause
e hypothalamus is the CNS structure that, as well as various other
functions, is specically devoted to maintaining body temperature and
the sleep-wake rhythm, as well as to maintaining water and salt balance
and regulating food intake.
In the hypothalamus, the anterior and preoptic nuclei are
responsible for cooling, whereas the posterior nucleus is devoted to
heating; these centres possess cells that are able to respond to variations
in body temperature, which is recorded from the temperature of the
blood that reaches the encephalon. When the temperature is higher
than physiological levels, the posterior nucleus releases noradrenaline,
which in turn stimulates the nuclei in the anterior hypothalamus,
culminating in a response that causes an increase in sweating and
peripheral vasodilatation and thus returning the system to a state of
equilibrium. It is specically the increase in noradrenaline which
results in sweating and hot ushes in menopausal women with the aim
of reducing raised body temperature [12].
Dopamine also plays an important role in thermoregulation in
that it too is devoted to maintaining a state of euthermia via the D2
receptors. As has long been known, bromocriptine, a dopamine
agonist, is able to increase the activity of the hypothalamic endogenous
opioid system (β-endorphins) on the mechanisms regulating body
temperature in menopause [13]. In fact, β-endorphins are also involved
in thermoregulatory homeostasis and inhibit the noradrenergic
neurons below the threshold at which heat loss is activated.
During fertile life, oestrogens play an important role in modifying
the synthesis, release and metabolism of many neurotransmitters,
including dopamine and melatonin, which are responsible for
modulating the hypothalamic and limbic systems.
It is therefore clear that the decrease in oestrogen levels from the
perimenopausal period until overt menopause is accompanied by
changes in function of these systems, which is of particular relevance to
thermoregulation and vasomotor stability.
e resultant outcome is connected with menopausal symptoms.
e menopausal changes therefore induce a temporary imbalance of
thermoregulation in the hypothalamus, modulating the homeostasis of
the body temperature to values below physiological levels, which are
then achieved by the dispersal of heat by means of vasodilatation and
profuse sweating.
Postmenopausally, the decrease in oestrogens reduces the
inhibitory activity of β-endorphins on noradrenaline and causes an
increase in activity of the noradrenergic system but also a reduction
of the dopaminergic system, which is signicantly less active than in
premenopausal women (Figures 2 and 3) [7,8].
All these mechanisms explain the positive eect of hormone
therapy, resulting in stimulation of the D2 dopaminergic receptors and
the subsequent attenuation of the menopausal symptoms associated
with hot ushes and sweating, with a consequent improvement also
in the psychological correlations and a decrease in the risk factors for
osteoporotic and cardiovascular diseases.
Melatonin levels and the time during which these levels remain
high during the night also dier during the various phases of life, with a
signicant decrease with advancing age; this explains why sleep is oen
disturbed and is of poorer quality in the elderly [14].
Perimenopausally, it has been shown that the reduction in
melatonin secretion precedes the increase in FSH in menopause.
Moreover, the instability of the ovarian hormones and their
uctuation during the perimenopausal period destabilises the
physiological circadian rhythm and the decrease in oestrogens can also
contribute signicantly to changes in mood and physiological well-
being.
A genuine problem that frequently occurs when a woman asks for
relief of the vasomotor disorders that aict her is represented by the
fact that, as is now well known, the traditional Hormone Replacement
erapy (HRT) is accepted and used by only a small percentage of
women (about 8%), as the literature reports that there is a state of fear
of an increased risk of breast cancer that in fact causes doctors not to
prescribe such drugs, although very oen it is the women themselves
who refuse to use them.
Short-term
symptoms
Medium-term
symptoms
Long-term
symptoms
−Menstrual irregularity
−Hot ushes
−Sweating
(including at night)
−Insomnia
−Anxiety
−Depression
−Asthenia
−Irritability
−Urogenital disorders
oVaginal dryness
oDyspareunia
oUrinary incontinence
−Cutaneous and mucosal atrophy
oCutaneous hypoelasticity
(increased wrinkles)
oAtrophy of the oral mucosa
oEye symptoms
−Obesity
−Osteoporosis
−Cardiovascolar
disorders
−Atherosclerosis
−Alzheimer’s
disease
Table 1: Schematic representation of the main short-term, medium-term and long-
term symptoms of menopausal women.
Figure 2: Heat control system during fertile life and changes in the
menopausal woman.
Figure 3: Mechanism of development of hot ushes in menopause.
Citation: Leo VD, Cappelli V, Sabatino AD, Morgante G (2014) Phyto-Oestrogens and Chaste Tree Berry: A New Option in the Treatment of Menopausal
Disorders. J Women’s Health Care 3: 182. doi:10.4172/2167-0420.1000182
Page 3 of 6
Volume 3 • Issue 5 • 1000182
J Women’s Health Care
ISSN: 2167-0420 JWHC, an open access journal
Hormone Replacement erapy (HRT)
A reasoned choice of the therapeutic protocol in terms of
preparation type, dosage, therapeutic regimen and route of
administration is essential for the rational use of HRT. As conrmed
by the results of the WHI study, dierent therapeutic strategies must be
chosen with an individualised risk-benet assessment. In recent years,
following a few clinical studies that had aroused considerable fear, the
therapeutic approaches to postmenopausal women have been reviewed
[15]. Additionally, new treatment protocols have been identied with
low oestrogen doses that are eective in controlling postmenopausal
symptoms and reducing the incidence of side eects and potential risks
associated with the duration of treatment (Table 2).
e reduction in the dose of oestrogens to be administered does
not preclude the fact that all women must undergo tests before starting
treatment. Women who take hormone therapy should undergo a clinical
follow-up at least once a year, including a gynaecological visit, updating
of the medical history, laboratory and instrumental tests and a lifestyle
assessment. Mammography must be performed, preferably within 12
months of the start of treatment [16]; increased breast density can be
attributed predominantly to the eects of the progestin component of
HRT [17,18].
e woman must be examined from an endocrine and metabolic
standpoint, the type of oestrogen and possibly the most suitable type
of progestin must be chosen, as well as the best route of administration
and the combination modality best suited to the individual [15].
e main aim of hormone replacement therapy is to improve the
quality of life of patients in spontaneous or surgical postmenopause who
are experiencing menopausal symptoms [2]: hot ushes [6], nocturnal
sweating, vaginal atrophy, dyspareunia, neurovegetative problems,
osteoporosis [3] or a familial history of osteoporosis, with high levels
of total cholesterol and low levels of HDL-cholesterol, and with a family
history of cardiovascular diseases [19-21]. HRT should be considered in
the absence of contraindications and aer discussing the potential risks
and benets with the woman [22]. HRT is contraindicated in women
with a positive history of breast cancer [23,24] or endometrial cancer
[25], in women with thromboembolic episodes [26] during pregnancy
or in those taking oral contraceptives, with any current liver diseases or,
at all events, with impaired liver function.
Phyto-oestrogens
In recent times, the pharmaceutical market has been enriched by
numerous products known as food supplements based predominantly
on phyto-oestrogens, or plant oestrogens, derived from soya and
combined with vitamins and other plant substances, which have made
them greatly appreciated by women, both for the relief of disorders
of the perimenopausal and overt menopausal period, and during the
fertile life. It is the gynaecologist’s task to identify the right products to
recommend to women based on the quantities and quality of substances
present.
Phyto-oestrogens are compounds that are present in many plants
with a very similar action to mammalian oestrogens.
However, some clarications are needed about phyto-oestrogens,
since they do not all have the same therapeutic ecacy.
ese products exert a gentle and balanced oestrogenic action
due to the active ingredients they contain; more precisely, by virtue of
their particular chemical structure, they are able to bind to oestrogen
receptors and thus exert biological activity of an oestrogenic or
antioestrogenic nature. e diversication of this eect depends on
their concentration, that of the oestrogens produced by the body and
on certain individual characteristics (tissue concentration of receptors
and enzymes involved in the metabolism of these hormones).
Phyto-oestrogens are commonly divided into three main classes:
isoavones, coumestans and lignans (a fourth category that of lactones
is of little therapeutic value) (Table 3). ey are ubiquitous in the
plant world (present in at least 300 varieties of plants, few of which
are edible). In terms of food sources, mention may be made of soya,
legumes and, albeit in small quantities, many types of fruits, vegetables
and wholegrain.
Soya, its derivatives (our, soya milk and tofu) and red clover
represent the main commercial sources of phyto-oestrogens.
Soya isoavones in particular have a higher oestrogenic activity
than other phyto-oestrogens. ey bind to the oestrogen receptor,
albeit with lesser anity, forming a receptor complex that functions in
a similar way. Many of the health-giving properties of isoavones are
attributable to the weak oestrogenic action of genistein and daidzein,
the two most important isoavones, and their interaction with the
oestrogen receptors that are distributed throughout the body. Genistein
has a seven-fold greater oestrogenic activity than daidzein.
As well as the biological signicance, the indications for phyto-
oestrogens are also now well known; these substances have a known
antioxidant and oestrogenic activity (they reduce disorders due to both
a deciency and an excess of oestrogens).
Recent studies have shown the progressive reduction in hot ushes
and sweating following treatment with phyto-oestrogens. Doses of 45-
90 mg of soya isoavones, equal to about 2-3 soya-based meals a day,
should be used to provide protection against hot ushes.
It has emerged from these studies that soya isoavones do not
stimulate endometrial growth and therefore they do not increase the
risk of endometrial or uterine tumours [27]. Other studies have shown
that the continuous administration of phyto-oestrogens derived from
soya isoavones exerts a protective action against cardiovascular
diseases and postmenopausal osteoporosis.
It has been shown that phyto-oestrogens exert a protective action
on blood vessels and against heart diseases. Following constant and
HORMONE REPLACEMENT THERAPY
Positive effects Risks
Reduction of menopausal symptoms Venous thromboembolism
Prevention of osteoporosis Cardiovascular risk
Increased trophism of the urogenital tract Risk of breast Ca
Table 2: Schematic representation of the main positive effects and possible risk
factors of the use of hormone replacement therapy (HRT).
ISOFLAVONES COUMESTANS LIGNANS
Genistein
− Soya and derivatives
Daidzein
− Legumes
Glycitein
− Clover
Biochanin A
− Whole grains
Formononetin
Coumestrol
− Beans, soya sprouts
4-Methoxycoumestrol
− Cloves, soya sprouts,
red clover, sunower
seeds
Enterodiol
− Linseed and sesame
seeds
Enterolactone
− Soya, hops, fruit and
vegetables, cereals
Table 3: Subdivision of classes and subclasses of phyto-oestrogens and principal
dietary sources.
Citation: Leo VD, Cappelli V, Sabatino AD, Morgante G (2014) Phyto-Oestrogens and Chaste Tree Berry: A New Option in the Treatment of Menopausal
Disorders. J Women’s Health Care 3: 182. doi:10.4172/2167-0420.1000182
Page 4 of 6
Volume 3 • Issue 5 • 1000182
J Women’s Health Care
ISSN: 2167-0420 JWHC, an open access journal
sustained intake, they can in fact reduce levels of triglycerides and low-
density lipoproteins (LDL or bad cholesterol) and increase levels of
high density cholesterol (HDL or good cholesterol) [28].
Isoavone supplements allow a better knowledge of the dosage
than the consumption of soya-rich foods, which is reected in greater
ecacy. e results can be appreciated more clearly aer the second
week of intake. In addition, these products do not cause any side eects.
e commercially available soya isoavone-based supplements
are not all equal. As well as high-quality products, unregulated
products and/or those of a low technological level can be found. Many
commercialised products refer to generic extracts of soya or isoavones
without specifying the type of isoavones they contain and exhibit a
dierent genistein/daidzein ratio from that found in nature; in addition,
some contain less active isoavones, such as glycitein.
Following the example of oral therapy, some soya isoavone-based
topical formulations have been marketed with the aim of treating and
preventing postmenopausal vulvovaginal symptoms. e availability of
products containing an adequate dose of soya isoavones has shown
to be eective, not only in curing vulvovaginal symptoms by more
continuous administration, but also in preventing their development
by periodic administration, in alternate 3-month cycles, which is met
with greater approval by the women.
Among other eects, oestrogens also possess an antioxidant activity,
thus inhibiting the formation of free radicals. Phytoestrogens have
also been shown to exert marked antioxidant, anti-inammatory and
antihypertensive activity. erefore, food supplements, in particular
multivitamins, represent a valid alternative to hormone replacement
therapy in menopausal woman.
Supplements that contain vitamin D and calcium as well as phyto-
oestrogens are indicated in the prevention of osteoporosis as a result
of their joint action of increasing intestinal absorption of calcium and
increasing its availability in bone, thus making the latter less fragile.
Combinations of phyto-oestrogens and other substances produce
an improvement in menopausal symptoms.
Over the years, there have been numerous combinations of phyto-
oestrogens and various other vitamin or benecial substances, but
recently pharmaceutical companies have particularly focussed on
some substances that can help relieve the disorders suered by women
in the peri- and postmenopausal period as much as possible. Various
substances have been studied and, of these, some deserve particular
mention, such as magnolia, lactobacilli, vitamin D and calcium, which
act specically on the disorders that women complain of most oen [4].
Vitamin D and calcium are very well known for their activity on bone
and therefore in the prevention of osteopenia and, in time, osteoporosis,
and their benecial properties are now conrmed.
In terms of the benecial activity of the combination of phyto-
oestrogens and probiotic lactic ferments, mention may be made of
Lactobacillus sporogenes (Bacillus coagulans), which reaches the distal
part of the small and large intestine in live form, where it germinates and
produces enzymes, vitamins and lactic acid, thus creating favourable
conditions for the absorption of calcium, magnesium, phosphorus,
iron and copper, but also trace elements and vitamins. In combination
with phyto-oestrogens, it is useful by virtue of its capacity for producing
glycosidase, an enzyme that releases the main active ingredients of
soya isoavones by cleaving their glycoside bond; lactobacilli therefore
improve the activity of phyto-oestrogens by stabilising the intestinal
bacterial ora and allowing the constant absorption of the active
ingredients.
A 2011 study shows that bioavailability varies with single doses
of two oral formulations of isoavones (genistein) with and without
lactobacilli, with a signicant increase in the peak plasma concentration
compared with the same dose of isoavones without lactobacilli.
A symptom that is oen associated with hot ushes in a large
number of women is a poorly tolerated state of anxiety that oen causes
a profound state of psychological prostration; this condition is also
oen correlated with a sense of constant tiredness and asthenia, with a
deterioration in the quality of rest and with a decrease in actual hours
of sleep.
In terms of this important symptom, the marked anti-anxiogenic
properties of magnolia extract are well known [29]. Magnolia extract
exerts a calming and comforting eect, without however causing
daytime drowsiness, and does not have the side eects that characterised
prescription anxiolytics. e main active ingredients are magnolol and
honokiol, which have modulating capacities on the GABAA receptors of
the cerebral limbic system, which is the centre devoted to emotions and
feelings. is explains how this substance can have benecial eects on
changes in the sleep-wake rhythm through a calming, muscle-relaxing
and balance-restoring action.
Magnolia extract also reduces blood cortisol levels, which are
increased in stress states; therefore, this substance also exhibits adaptive
activity in situations of severe psychological and physical stress [30].
Recent studies comparing magnolia extract with diazepam in
women who have stress-related anxiety and are overweight have shown
its equivalent ecacy to that of the drug [31,32].
Because postmenopause is a condition in which weight gain
represents a clinical condition that aects many women and in most
cases is associated with anxiety, this mechanism is converted into a
greater sensation of hunger with a preference for carbohydrates and
simple sugars, causing a sort of vicious cycle.
ere have been no reports of relevant side eects for any of these
ingredients and there is optimal compliance on the part of the women
mainly because they know they are taking natural products that do not
negatively interfere with their own genital tract and with the risk of
developing breast cancer.
Chaste tree berry
Particular mention should be made of chaste tree berry, which is
characterised by a few specic benecial properties for postmenopausal
women.
Chaste tree berry (Vitex Agnus-castus) is a phytocomplex
containing glycosides, avonoids, terpenes and alkaloids, and its main
active ingredient is agnuside; it has always been known as a product
that can resolve premenstrual syndrome problems in women of fertile
age and recently its usefulness has also been observed in menopause,
particularly in respect of vasomotor symptoms [5]. ese data have
suggested that there may be an analogy between this syndrome and
menopausal symptoms. e mechanism of action of chaste tree berry
involves an increase in hypothalamic dopaminergic tone; it expresses
a binding anity with oestrogen α (ERα) and β (ERβ) receptors and
stimulates m-RNA expression by the progesterone receptor (PR
expression) and that of pS2 (presenelin-2), another oestrogen-inducible
gene (Figure 4) [5,33]. Dopamine is the main neurotransmitter that
Citation: Leo VD, Cappelli V, Sabatino AD, Morgante G (2014) Phyto-Oestrogens and Chaste Tree Berry: A New Option in the Treatment of Menopausal
Disorders. J Women’s Health Care 3: 182. doi:10.4172/2167-0420.1000182
Page 5 of 6
Volume 3 • Issue 5 • 1000182
J Women’s Health Care
ISSN: 2167-0420 JWHC, an open access journal
controls the secretion of prolactin (Prl) by way of inhibition. ere
are clear data to show how it corrects the deciency of progesterone
in the corpus luteum during fertile life, by its action as a dopamine
agonist, and how it causes an improvement in menopausal symptoms
by reducing Prl levels.
in recent years, it has also emerged that, through its dopaminergic
action, chaste tree berry is also capable of engendering benecial eects
by improving the emotional symptoms typical of the menopause,
because a decrease in dopaminergic tone is correlated with psychological
symptoms [34].
A 2011 study has shown how the daily incidence of hot ushes
aer 8 weeks of treatment is signicantly decreased in women taking
chaste tree berry compared with a group taking placebo (Figure 5)
[35]; in addition, Kupperman’s index in the group treated with chaste
tree berry showed a statistically signicant dierence in terms of
the severity of hot ushes, night-time sweating, insomnia, anxiety,
depression, asthenia and headache compared with the control group.
However, there are few studies to date that focus on the possible activity
of chaste tree berry on sexual desire in menopausal women, although
data available to us regarding the dopaminergic and opioid action also
suggest the possibility of a topical formulation for treating dyspareunia
in these women [36].
is evidence suggests that the combination of phyto-oestrogens
and chaste tree berry can convincingly resolve the vasomotor and
psychological symptoms typical of peri- and postmenopausal women.
On the basis of these considerations, the potential availability of
a complete product consisting of phyto-oestrogens, chaste tree berry
and magnolia extract can be particularly useful, not only in resolving
vasomotor symptoms, but also in acting on the neuroendocrine
component that is the main cause of anxiety and certain neurovegetative
symptoms, such as sweating and night-time awakenings
Correlations Between Premenstrual Syndrome and
Vasomotor Symptoms in Menopause
ere is a correlation between premenstrual syndrome and
vasomotor symptoms, i.e. women who have suered from premenstrual
syndrome during their fertile life show more severe vasomotor
symptoms in the postmenopausal period.
One of the factors predominantly involved in the aetiopathogenesis
of both conditions is certainly the change in the dopaminergic and
serotoninergic systems, so that the administration of dopaminergic
drugs, such as bromocriptine and/or cabergoline, can improve both
sets of symptoms by normalising the dopaminergic and serotoninergic
systems.
e success of administration of chaste tree berry in women
with premenstrual syndrome is due to the restoration of a normal
dopaminergic tone. Postmenopausally, the combination of phyto-
oestrogens and chaste tree berry produces a more benecial eect on
dopaminergic tone with a more signicant reduction in the incidence
of vasomotor symptoms and, particularly, hot ushes.
e simultaneous presence of magnolia also encourages more
physiological sleep with fewer night-time awakenings.
Conclusions
For all of the above reasons, soya isoavones, which, in the light
of numerous clinical studies and according to reports from women,
appear to act by improving vasomotor symptoms, represent a valid
alternative to HRT. e properties of isoavones are not limited to
vasomotor symptoms alone, but they also have positive eects on bone
mass in that oestrogen β receptors, with which soya phyto-oestrogens
have a greater anity, are strongly expressed in bone.
In addition, isoavones exert an antioxidant action, reducing free
radicals, and have an inhibitory eect on the enzyme aromatase that
converts androgens to oestrogens in adipose tissue and increases the
risk of endometrial and breast cancer. Products used postmenopausally
not only contain phyto-oestrogens, but are oen combined with
calcium, vitamin D and other components, as is the case with the latest
preparation in which magnolia and in particular chaste tree berry
contribute signicantly to improving vasomotor and neurovegetative
symptoms.
References
1. Al-Anazi AF, Qureshi VF, Javaid K, Qureshi S (2011) Preventive effects of
phytoestrogens against postmenopausal osteoporosis as compared to the
available therapeutic choices: An overview. J Nat Sci Biol Med 2: 154-163.
2. National Institutes of Health (2005) National Institutes of Health State-of-
the-Science Conference statement: management of menopause-related
symptoms. Ann Intern Med 142: 1003-1013.
3. North American Menopause Society (2006) Management of osteoporosis
in postmenopausal women: 2006 position statement of The North American
Menopause Society. Menopause 13: 340-367.
4. Mucci M, Carraro C, Mancino P, Monti M, Papadia LS, et al. (2006) Soy
isoavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium.
Controlled clinical study in menopause. Minerva Ginecol 58: 323-334.
Figure 4: Mechanism of action of chaste tree berry on hot ushes.
Figure 5: Reduction in the daily frequency of hot ushes after 2, 4, 6
and 8 weeks of treatment with chaste tree berry in menopausal women
compared with women treated with placebo only.
p values <0.05 were considered signicant; **=p<0.01 and ***=p<0.001.
Citation: Leo VD, Cappelli V, Sabatino AD, Morgante G (2014) Phyto-Oestrogens and Chaste Tree Berry: A New Option in the Treatment of Menopausal
Disorders. J Women’s Health Care 3: 182. doi:10.4172/2167-0420.1000182
Page 6 of 6
Volume 3 • Issue 5 • 1000182
J Women’s Health Care
ISSN: 2167-0420 JWHC, an open access journal
5. Lucks BC, Sørensen J, Veal L (2002) Vitexagnus-castus essential oil and
menopausal balance: a self-care survey. Complement Ther Nurs Midwifery 8:
148-154.
6. Ohayon MM (2006) Severe hot ashes are associated with chronic insomnia.
Arch Intern Med 166: 1262-1268.
7. Ettinger B, Pressman A, Silver P (1999) Effect of age on reasons for initiation
and discontinuation of hormone replacement therapy. Menopause 6: 282-289.
8. Kronenberg F (1990) Hot ashes: epidemiology and physiology. Ann N Y Acad
Sci 592: 52-86.
9. Gambacciani M, Pepe A (2009) Vasomotor symptoms and cardiovascular risk.
Climacteric 12 Suppl 1: 32-35.
10. Maki PM, Drogos LL, Rubin LH, Banuvar S, Shulman LP, et al. (2008) Objective
hot ashes are negatively related to verbal memory performance in midlife
women. Menopause 15: 848-856.
11. Lisabeth L, Bushnell C (2012) Stroke risk in women: the role of menopause and
hormone therapy. Lancet Neurol 11: 82-91.
12. Rapkin AJ (2007) Vasomotor symptoms in menopause: physiologic condition
and central nervous system approaches to treatment. Am J Obstet Gynecol
196: 97-106.
13. Cagnacci A, Melis GB, Soldani R, Gambacciani M, Paoletti AM, et al. (1989)
Regulation of body temperature in postmenopausal women: interactions
between bromocriptine and the endogenous opioid system. Life Sci 44: 1395-
1402.
14. Blaicher W, Speck E, Imhof MH, Gruber DM, Schneeberger C, et al. (2000)
Melatonin in postmenopausal females. Arch Gynecol Obstet 263: 116-118.
15. AACE Menopause Guidelines Revision Task Force (2011) American
Association of clinical Endocrinologists medical guidelines for clinical practice
for the diagnosis and treatment of menopause. Endocr Pract. 12: 315-337.
16. Glass AG, Lacey JV Jr, Carreon JD, Hoover RN (2007) Breast cancer
incidence, 1980-2006: combined roles of menopausal hormone therapy,
screening mammography, and estrogen receptor status. J Natl Cancer Inst 99:
1152-1161.
17. Grady D, Vittinghoff E, Lin F, Hanes V, Ensrud K, et al. (2007) Effect of ultra-
low-dose transdermal estradiol on breast density in postmenopausal women.
Menopause 14: 391-396.
18. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, et
al. (2006) Effects of conjugated equine estrogens on breast cancer and
mammography screening in postmenopausal women with hysterectomy. JAMA
295: 1647-1657.
19. Alonso de Leciñana M1, Egido JA, Fernández C, Martínez-Vila E, Santos S, et
al. (2007) Risk of ischemic stroke and lifetime estrogen exposure. Neurology
68: 33-38.
20. Lemaitre RN, Weiss NS, Smith NL, Psaty BM, Lumley T, et al. (2006) Esteried
estrogen and conjugated equine estrogen and the risk of incident myocardial
infarction and stroke. Arch Intern Med 166: 399-404.
21. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, et al. (2007) Estrogen
therapy and coronary-artery calcication. N Engl J Med 356: 2591-2602.
22. Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, et al. (2005)
Menopausal symptoms and treatment-related effects of estrogen and progestin
in the Women’s Health Initiative. Obstet Gynecol 105: 1063-1073.
23. Bernstein L (2006) The risk of breast, endometrial and ovarian cancer in users
of hormonal preparations. Basic Clin Pharmacol Toxicol 98: 288-296.
24. Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, et al.
(2008) Estrogen plus progestin and breast cancer detection by means of
mammography and breast biopsy. Arch Intern Med 168: 370-377.
25. American College of Obstetricians and Gynecologists Committee on Gynecologic
Practice (2006) ACOG committee opinion. No. 337: Noncontraceptive uses of
the levonorgestrel intrauterine system. Obstet Gynecol 107: 1479-1482.
26. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, et al. (2007) Hormone
therapy and venous thromboembolism among postmenopausal women: impact
of the route of estrogen administration and progestogens: the ESTHER study.
Circulation 115: 840-845.
27. Palacios S, Pornel B, Vázquez F, Aubert L, Chantre P, et al. (2010) Long-
term endometrial and breast safety of a specic, standardized soy extract.
Climacteric 13: 368-375.
28. Baum JA, Teng H, Erdman JW Jr, Weigel RM, Klein BP, et al. (1998) Long-term
intake of soy protein improves blood lipid proles and increases mononuclear
cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic,
postmenopausal women. Am J Clin Nutr 68: 545-551.
29. Alexeev M, Grosenbaugh DK, Mott DD, Fisher JL (2012) The natural products
magnolol and honokiol are positive allosteric modulators of both synaptic and
extra-synaptic GABA(A) receptors. Neuropharmacology 62: 2507-2514.
30. Kalman DS, Feldman S, Feldman R, Schwartz HI, Krieger DR, et al. (2008)
Effect of a proprietary Magnolia and Phellodendron extract on stress levels in
healthy women: a pilot, double-blind, placebo-controlled clinical trial. Nutr J.
21:7-11.
31. Seo JJ, Lee SH, Lee YS, Kwon BM, Ma Y, et al. (2007) Anxiolytic-like effects of
obovatol isolated from Magnolia obovata: involvement of GABA/benzodiazepine
receptors complex. Prog Neuropsychopharmacol Biol Psychiatry 31: 1363-
1369.
32. Benvenuti C, Setnikar I (2011) Effect of Lactobacillus sporogenes on oral
isoavones bioavailability: single dose pharmacokinetic study in menopausal
women. Arzneimittelforschung 61: 605-609.
33. Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, et al. (2001) Evaluation of
estrogenic activity of plant extracts for the potential treatment of menopausal
symptoms. J Agric Food Chem 49: 2472-2479.
34. van Die MD, Burger HG, Teede HJ, Bone KM (2009) Vitex agnus-castus
(Chaste-Tree/Berry) in the treatment of menopause-related complaints. J Altern
Complement Med 15: 853-862.
35. Abbaspoor Z, Azam Hajikhani NA, Afsharl P (2011) Effects of Vitex-agnus-
castus on menopausal early symptoms in postmenopausal women: a
randomized double-blind, placebo-controlled study. Brtt J Med & Med Res
1:132-140.
36. Mazaro-Costa R, Andersen ML, Hachul H, Tuk S (2010) Medicinal plants as
alternative treatments for female sexual dysfunction: utopian vision or possible
treatment in climacteric women? J Sex Med 7: 3695-3714.
Citation: Leo VD, Cappelli V, Sabatino AD, Morgante G (2014) Phyto-
Oestrogens and Chaste Tree Berry: A New Option in the Treatment of
Menopausal Disorders. J Women’s Health Care 3: 182. doi:10.4172/2167-
0420.1000182
Submit your next manuscript and get advantages of
OMICS Group submissions
Unique features:
User friendly/feasible website-translation of your paper to 50 world’s leading languages
Audio Version of published paper
Digital articles to share and explore
Special features:
350 Open Access Journals
30,000 editorial team
21 days rapid review process
Quality and quick editorial, review and publication processing
Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
Sharing Option: Social Networking Enabled
Authors, Reviewers and Editors rewarded with online Scientic Credits
Better discount for your subsequent articles
Submit your manuscript at: http://www.omicsonline.org/submission